Press release
Skanska announces decreased scope for facility in Everett, Washington, USA, worth USD 49M, about SEK 510M
Skanska announces that Pfizer has reduced the scope of work on its 25,000 square-meter biomanufacturing facility in Everett, Washington, USA, which Skanska previously was contracted to construct. The order reduction amounts to USD 49M, about SEK 510M, which will be deducted from the US order bookings for the first quarter 2024.
The initial contract with Seagen, who recently was acquired by Pfizer, was worth USD 215M, about SEK 2.2 billion, and was announced August 4, 2023.
For further information please contact:
Daniela Arellano, Communications Director, Skanska USA, tel +1 213 317 4977
Andreas Joons, Press Officer, Skanska AB, tel +46 (0)10 449 04 94
Direct line for media, tel +46 (0)10 448 88 99
This and previous releases can also be found at www.skanska.com.
Media Relations contacts
Are you a journalist looking for information about Skanska or have questions about our operations? Our Media Relations team can help with press inquiries, interviews, background information and access to relevant resources.
Jacob Birkeland
Head of Media Relations & Public Affairs
Andreas Joons
Media Relations Manager
Olof Rundgren
Media Relations Manager